نتایج جستجو برای: interferon beta 1b

تعداد نتایج: 269096  

2011
Francesca Bagnato

Recombinant interferon beta-1b (IFNβ-1b) was the first approved disease-modifying therapy for patients with multiple sclerosis (MS) by the world regulatory agencies for medical drugs and devices. IFNβ-1b significantly decreases the inflammatory component of MS but still has doubtable effect on the neurodegenerative component. This article appraises the beneficial effects of IFNβ-1b on clinical ...

Journal: :Journal of neurology, neurosurgery, and psychiatry 2003
C Milanese L La Mantia R Palumbo V Martinelli A Murialdo M Zaffaroni D Caputo R Capra R Bergamaschi

BACKGROUND Interferon beta 1b (Betaferon) and 1a (Avonex) were licensed in Italy for treating relapsing-remitting multiple sclerosis in February 1996 and August 1997, respectively. OBJECTIVES To evaluate the effectiveness of these agents on the basis of clinical experience in northern Italian multiple sclerosis centres. DESIGN Clinical data on patients with relapsing-remitting multiple scle...

2012
Chiara Zecca Nikhil Yawalkar Claudio Gobbi

BACKGROUND The spectrum of side effects related to interferon beta-1b (INF-1b) treatment may compromise long-term adherence. METHODS Five INF-1b-treated multiple sclerosis patients with poor skin tolerability and clinical stability were instructed to dissolve the established (250 μg) INF-1b dose in half (0.5 mL) the standard diluent (1.0 mL, 0.54% sodium chloride solution), and were followed ...

2009
Damiano Paolicelli Vita Direnzo Maria Trojano

Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFNbeta)-1b represents the pioneer of those therapies....

Introduction : There are several introduced forms of treatment for patients with relapse-remitting & secondary progressive multiple sclerosis in recent years. Interferon beta-1b (Betaferon) is the first of these agents that administered subcutaneously once in every two days. Case Report: This report is related to a 33 years old female. After 6 times of Betaferon injection vasculitis necrotiz...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید